You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1820 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
May 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    olaparib - For the treatment of metastatic castration resistant prostate cancer (mCRPC), according to clinical criteria
Nov 2023
Regimen
Intent: Palliative
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Feb 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
ODB - General Benefit
    hydroxyurea
Mar 2023
Regimen
Intent: Palliative
Sep 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Jul 2020
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Palliative
Funding:
New Drug Funding Program
    Siltuximab - Multicentric Castleman’s Disease (MCD)
Nov 2017
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Jun 2020
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Jun 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Adjuvant
May 2019

Pages